Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 6, 1998, Pages 427-430

  Vincent, J ^a   Dogolo, L ^a   Baris, B A ^a   Willavize, S A ^a   Teng, R ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0031752614     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01691577     Document Type: Article

References (14)

1. Neu HC, Chin N-X: In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy (1994) 38:2615-2622
2. Briggs-Gooding B, Jones RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclonaphthyridone. Antimicrobial Agents and Chemotherapy (1993) 37:349-353
3. Klugman KP, Wasas AJ: In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy (1995) 36:873-874
4. Felmingham D, Robbins MJ, Ingley K, Mathias I, Bhogal H, Leakey A, Ridgway GL, Grüneberg RN: In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B:43-49
5. Child J, Andrews J, Boswell F, Brenwald N, Wise R: The in-vitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Journal of Antimicrobial Chemotherapy (1995) 35:869-876
6. Endtz HP, Mouton JW, Den Hollander JG, Van den Braak N, Verbrugh HA: Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Antimicrobial Agents and Chemotherapy (1997) 41:1146-1149
7. Gootz TD, Brighty KE, Anderson MR, Schmieder BJ, Haskell SL, Sutcliffe JA, Castaldi MJ, McGuirk PR: In vitro activity of CP-99,219, a novel 7-(3-azabicyclo [3.1.0] hexyl)-naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Disease (1994) 19:235-243
8. Teng R, Harris SC, Nix DE, Schentag JJ, Foulds G, Liston TE: Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Journal of Antimicrobial Chemotherapy (1995) 36:385-394
9. Girard AE, Girard D, Gootz TD, Faiella JA, Cimochowski CR: In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrobial Agents and Chemotherapy (1995) 39:2210-2216
10. Vincent J, Venitz J, Teng R, Baris BA, Willavize SA, Polzer RJ, Friedmen HL: Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B:75-80
11. Teng R, Tensfeldt TG, Liston TE, Foulds G: Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reverse-phase high-performance liquid chromatography. Journal of Chromatography (1996) 675:53-59
12. Karabalut N, Drusano GL: Pharmacokinetics of the quinolone antimicrobial agents. In: Hooper DC, Wolfson JS (eds): Quinolone Antimicrobial Agents. American Society for Microbiology, Washington, DC (1993), pp. 195-223
13. Tsubakihara Y, Itoh T, Kitamura E, Okada N, Nakanishi I, Iida N: Pharmacokinetics of ofloxacin in patients with severe chronic renal failure. Reviews of Infectious Diseases (1989) 11, Supplement 5:1006-1007
14. Stuck AE, Frey FJ, Heizmann R, Brandt R, Weidekamm E: Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis. Antimicrobial Agents and Chemotherapy (1989) 33:373-381